专利检索 ap:("Cornell University" OR "The Research Foundation for The State University of New York") AND inv:"MATHISON, Megumi" 第 1 页

1.

发明授权
ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM 有权

公开(公告)号：EP3329779B1

公开(公告)日：2019-06-05

申请号：EP17194540.5

申请日：2013-11-01

申请人： Cornell University , The Research Foundation for The State University of New York

发明人： CRYSTAL, Ronald G. , ROSENGART, Todd K. , GERSCH, Robert , MATHISON, Megumi

IPC分类号： A01N63/00 , C12N5/00 , C07K14/52 , A61K38/00 , C07K14/00 , A61K48/00 , A61K38/17 , C07K14/49

2.

发明授权
ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM 有权
标题翻译：血管生成调节增强心室肌细胞成纤维细胞的心肌细胞重编程

公开(公告)号：EP2914114B1

公开(公告)日：2017-10-04

申请号：EP13850199.4

申请日：2013-11-01

申请人： Cornell University , The Research Foundation for The State University of New York

发明人： CRYSTAL, Ronald G. , ROSENGART, Todd K. , GERSCH, Robert , MATHISON, Megumi

IPC分类号： A01N63/00 , C12N5/00 , C07K14/52 , A61K38/00 , C07K14/00 , A61K48/00

CPC分类号： A61K38/1866 , A61K38/00 , A61K38/1709 , A61K48/00 , A61K48/005 , C07K14/47 , C07K14/49 , C07K14/52 , C12N2710/10341 , C12N2740/15041

3.

发明公开
ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM 审中-公开

公开(公告)号：EP3329779A1

公开(公告)日：2018-06-06

申请号：EP17194540.5

申请日：2013-11-01

申请人： Cornell University , The Research Foundation for The State University of New York

发明人： CRYSTAL, Ronald G. , ROSENGART, Todd K. , GERSCH, Robert , MATHISON, Megumi

IPC分类号： A01N63/00 , C12N5/00 , C07K14/52 , A61K38/00 , C07K14/00 , A61K48/00 , A61K38/17 , C07K14/49

CPC分类号： A61K38/1866 , A61K38/00 , A61K38/1709 , A61K48/00 , A61K48/005 , C07K14/47 , C07K14/49 , C07K14/52 , C12N2710/10341 , C12N2740/15041

摘要： Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).